북미의 사코페니아 치료 시장 전망(-2030년) : 지역별 분석 - 치료 유형별, 유통채널별, 지역별 분석

The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030.

Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market

The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US.

Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.

North America Sarcopenia Treatment Market Overview

The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region.

Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses.

North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Sarcopenia Treatment Market Segmentation

The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022.

In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022.

By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Sarcopenia Treatment Market - Key Industry Dynamics

• 4.1 North America Sarcopenia Treatment Market - Key Industry Dynamics
• 4.2 Market Drivers
  • 4.2.1 Upsurge in Geriatric Population
  • 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
• 4.3 Key Market Restraints:
  • 4.3.1 Unavailability of Direct Interventions
• 4.4 Key Market Opportunities:
  • 4.4.1 Products in Clinical Trial Phases
• 4.5 Future Trends:
  • 4.5.1 Rising Awareness About Sarcopenia
• 4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - North America Market Analysis

• 5.1 North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
• 5.2 North America Sarcopenia Treatment Market Forecast and Analysis

6. North America Sarcopenia Treatment Market Analysis - By Treatment Type

• 6.1 Vitamin D and Calcium Supplement
  • 6.1.1 Overview
  • 6.1.2 Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
• 6.2 Protein Supplement
  • 6.2.1 Overview
  • 6.2.2 Protein Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
• 6.3 Vitamin B12 Supplement
  • 6.3.1 Overview
  • 6.3.2 Vitamin B12 Supplement: North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
• 6.4 Others
  • 6.4.1 Overview
  • 6.4.2 Others : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. North America Sarcopenia Treatment Market Analysis - By Distribution Channel

• 7.1 Pharmacies
  • 7.1.1 Overview
  • 7.1.2 Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
• 7.2 Retail Channels
  • 7.2.1 Overview
  • 7.2.2 Retail Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
• 7.3 Online Channels
  • 7.3.1 Overview
  • 7.3.2 Online Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
• 7.4 Others
  • 7.4.1 Overview
  • 7.4.2 Others : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. North America Sarcopenia Treatment Market - Country Analysis

• 8.1 North America
  • 8.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
    • 8.1.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
    • 8.1.1.2 United States Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 8.1.1.2.1 United States Sarcopenia Treatment Market Breakdown by Treatment Type
      • 8.1.1.2.2 United States Sarcopenia Treatment Market Breakdown by Distribution Channel
    • 8.1.1.3 Canada Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 8.1.1.3.1 Canada Sarcopenia Treatment Market Breakdown by Treatment Type
      • 8.1.1.3.2 Canada Sarcopenia Treatment Market Breakdown by Distribution Channel
    • 8.1.1.4 Mexico Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 8.1.1.4.1 Mexico Sarcopenia Treatment Market Breakdown by Treatment Type
      • 8.1.1.4.2 Mexico Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

• 9.1 Overview
• 9.2 Growth Strategies in the Sarcopenia Treatment Market
• 9.3 Inorganic Growth Strategies
  • 9.3.1 Overview
• 9.4 Organic Growth Strategies
  • 9.4.1 Overview

10. Company Profiles

• 10.1 Abbott Laboratories
  • 10.1.1 Key Facts
  • 10.1.2 Business Description
  • 10.1.3 Products and Services
  • 10.1.4 Financial Overview
  • 10.1.5 SWOT Analysis
  • 10.1.6 Key Developments
• 10.2 Bayer AG
  • 10.2.1 Key Facts
  • 10.2.2 Business Description
  • 10.2.3 Products and Services
  • 10.2.4 Financial Overview
  • 10.2.5 SWOT Analysis
  • 10.2.6 Key Developments
• 10.3 Metagenics LLC
  • 10.3.1 Key Facts
  • 10.3.2 Business Description
  • 10.3.3 Products and Services
  • 10.3.4 Financial Overview
  • 10.3.5 SWOT Analysis
  • 10.3.6 Key Developments
• 10.4 Nestle Health Science SA
  • 10.4.1 Key Facts
  • 10.4.2 Business Description
  • 10.4.3 Products and Services
  • 10.4.4 Financial Overview
  • 10.4.5 SWOT Analysis
  • 10.4.6 Key Developments
• 10.5 Novartis AG
  • 10.5.1 Key Facts
  • 10.5.2 Business Description
  • 10.5.3 Products and Services
  • 10.5.4 Financial Overview
  • 10.5.5 SWOT Analysis
  • 10.5.6 Key Developments
• 10.6 Pfizer Inc
  • 10.6.1 Key Facts
  • 10.6.2 Business Description
  • 10.6.3 Products and Services
  • 10.6.4 Financial Overview
  • 10.6.5 SWOT Analysis
  • 10.6.6 Key Developments
• 10.7 Sanofi SA
  • 10.7.1 Key Facts
  • 10.7.2 Business Description
  • 10.7.3 Products and Services
  • 10.7.4 Financial Overview
  • 10.7.5 SWOT Analysis
  • 10.7.6 Key Developments
• 10.8 Amway Corp
  • 10.8.1 Key Facts
  • 10.8.2 Business Description
  • 10.8.3 Products and Services
  • 10.8.4 Financial Overview
  • 10.8.5 SWOT Analysis
  • 10.8.6 Key Developments
• 10.9 GSK Plc
  • 10.9.1 Key Facts
  • 10.9.2 Business Description
  • 10.9.3 Products and Services
  • 10.9.4 Financial Overview
  • 10.9.5 SWOT Analysis
  • 10.9.6 Key Developments
• 10.10 Makers Nutrition LLC
  • 10.10.1 Key Facts
  • 10.10.2 Business Description
  • 10.10.3 Products and Services
  • 10.10.4 Financial Overview
  • 10.10.5 SWOT Analysis
  • 10.10.6 Key Developments

11. Appendix

• 11.1 About The Insight Partners
• 11.2 Glossary of Terms